Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: Interim analysis

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 159-163

  Nishimura, S ^a   Tsuda, H ^a   Hashiguchi, Y ^a   Kokawa, K ^b   Nishimura, R ^c   Ishiko, O ^d   Kamiura, S ^e   Hasegawa, K ^f   Umesaki, N ^b  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f Inamino Hospital   (Japan)

Author keywords

Chemotherapy; Doxorubicin; Irinotecan; Phase II study; Platinum refractory ovarian cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 33846839568     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00728.x     Document Type: Article

References (18)

1. Sugiyama T, Komai K, Kamura T, Nozawa S. Clinical Oncology, 3rd edn. Tokyo, Japan: Gan To Kagaku Ryouhousya, 2003:823-41.
2. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
4. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
5. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2000;18:1062-7.
6. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
7. Hoskins WJ, Young RC, Markman M, Perez CA, Barakat R, Randall M. Principle and practice of gynecologic oncology, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:489-559.
8. Takeuchi S, Takamizawa H, Takeda Y et al. An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers [in Japanese]. Gan To Kagaku Ryoho 1991;18:579-84.
9. Bodurka DC, Levenback C, Wolf JK et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003;21:291-7.
10. Sugiyama T, Yakushiji M, Nishida T et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 1998;128:211-8.
11. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987;47:3973-9.
12. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992;50:760- 6.
13. Negoro S, Uejima H, Takeda T et al. A phase II study of irinotecan and doxorubicin in patients with refractory or relapsed small-cell lung cancer. Annals Oncol 2000;11:109.
14. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003;21(Suppl. 10):187-93.
15. Hwang JJ, Marshall JL, Rizvi N. Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin. Oncology (Williston Park) 2003;17(5 Suppl. 5):46-51.
16. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 2003;21:2856-9.
17. Hochster H, Plimack ER, Runowicz CD et al. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:120-6.
18. Francis P, Schneider J, Hann L et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8.